Advertisement

FDA spells out rules for new endpoint: Metastasis-free survival

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

It’s official, FDA is recognizing a new endpoint that seems especially well suited for prostate cancer: metastasis-free survival, or MFS for short.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Advertisement
Advertisement
Paul Goldberg
Editor & Publisher
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
Advertisement
Advertisement